Biomerica Future Growth
Future criteria checks 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Biomerica.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
Medical Equipment earnings growth | 16.6% |
Revenue growth rate | n/a |
Future return on equity | n/a |
Analyst coverage | None |
Last updated | n/a |
Recent future growth updates
Recent updates
Is Biomerica (NASDAQ:BMRA) In A Good Position To Deliver On Growth Plans?
Dec 20Here's Why We're Watching Biomerica's (NASDAQ:BMRA) Cash Burn Situation
Aug 31We're Keeping An Eye On Biomerica's (NASDAQ:BMRA) Cash Burn Rate
Mar 04Amazon starts selling Biomerica's Aware Breast Self Exam device, EZ Detect test
Sep 29Biomerica: One To Watch Closely For The Future, But From The Sidelines For Now
Sep 09Biomerica reports FY results
Aug 29Biomerica stock jumps after Walmart to begin selling co's Aware Breast Self Exam device
Jul 14Most Shareholders Will Probably Find That The CEO Compensation For Biomerica, Inc. (NASDAQ:BMRA) Is Reasonable
Dec 03Biomerica (NASDAQ:BMRA) Is In A Good Position To Deliver On Growth Plans
Dec 02Is Biomerica Stock A Buy Or Sell After Q4 Earnings? Catalysts To Watch Into 2022
Sep 15Biomerica (BMRA) Investor Presentation - Slideshow
Jun 14Companies Like Biomerica (NASDAQ:BMRA) Are In A Position To Invest In Growth
Jun 13Biomerica, Inc.'s (NASDAQ:BMRA) Profit Outlook
Apr 04Should You Review Recent Insider Transactions At Biomerica, Inc. (NASDAQ:BMRA)?
Mar 08Companies Like Biomerica (NASDAQ:BMRA) Are In A Position To Invest In Growth
Feb 10The Biomerica (NASDAQ:BMRA) Share Price Has Soared 405%, Delighting Many Shareholders
Jan 15Biomerica soars as its COVID-19 antigen test wins European nod
Jan 12When Will Biomerica, Inc. (NASDAQ:BMRA) Become Profitable?
Dec 20Biomerica clinical trial for IBS nears enrollment completion
Dec 09How Much Does Biomerica's (NASDAQ:BMRA) CEO Make?
Nov 23In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Biomerica has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
8/31/2024 | 6 | -6 | -5 | -5 | N/A |
5/31/2024 | 5 | -6 | -5 | -5 | N/A |
2/29/2024 | 5 | -6 | -5 | -5 | N/A |
11/30/2023 | 6 | -6 | -5 | -5 | N/A |
8/31/2023 | 5 | -6 | -6 | -6 | N/A |
5/31/2023 | 5 | -7 | -6 | -5 | N/A |
2/28/2023 | 10 | -7 | -9 | -9 | N/A |
11/30/2022 | 16 | -6 | -5 | -5 | N/A |
8/31/2022 | 19 | -5 | -2 | -2 | N/A |
5/31/2022 | 19 | -5 | -1 | 0 | N/A |
2/28/2022 | 15 | -4 | 3 | 3 | N/A |
11/30/2021 | 11 | -7 | -1 | -1 | N/A |
8/31/2021 | 7 | -7 | -4 | -4 | N/A |
5/31/2021 | 7 | -7 | -6 | -5 | N/A |
2/28/2021 | 9 | -6 | -8 | -8 | N/A |
11/30/2020 | 6 | -5 | -7 | -7 | N/A |
8/31/2020 | 7 | -4 | -6 | -6 | N/A |
5/31/2020 | 7 | -2 | -4 | -4 | N/A |
2/29/2020 | 5 | -3 | -2 | -2 | N/A |
11/30/2019 | 5 | -2 | -2 | -2 | N/A |
8/31/2019 | 5 | -2 | -2 | -1 | N/A |
5/31/2019 | 5 | -2 | -2 | -2 | N/A |
2/28/2019 | 5 | -2 | -2 | -2 | N/A |
11/30/2018 | 5 | -2 | -2 | -2 | N/A |
8/31/2018 | 5 | -2 | -2 | -2 | N/A |
5/31/2018 | 6 | -1 | N/A | -1 | N/A |
2/28/2018 | 6 | -1 | N/A | -1 | N/A |
11/30/2017 | 6 | -1 | N/A | -1 | N/A |
8/31/2017 | 6 | -1 | N/A | -1 | N/A |
5/31/2017 | 6 | -1 | N/A | -1 | N/A |
2/28/2017 | 6 | -2 | N/A | 0 | N/A |
11/30/2016 | 6 | -2 | N/A | 0 | N/A |
8/31/2016 | 5 | -1 | N/A | 0 | N/A |
5/31/2016 | 5 | -1 | N/A | 0 | N/A |
2/29/2016 | 5 | 0 | N/A | 0 | N/A |
11/30/2015 | 5 | 0 | N/A | -1 | N/A |
8/31/2015 | 5 | 0 | N/A | -1 | N/A |
5/31/2015 | 5 | 0 | N/A | 0 | N/A |
2/28/2015 | 5 | 0 | N/A | 0 | N/A |
11/30/2014 | 5 | 0 | N/A | 0 | N/A |
8/31/2014 | 5 | 0 | N/A | 0 | N/A |
5/31/2014 | 5 | 0 | N/A | -1 | N/A |
2/28/2014 | 5 | 0 | N/A | -1 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if BMRA's forecast earnings growth is above the savings rate (2.6%).
Earnings vs Market: Insufficient data to determine if BMRA's earnings are forecast to grow faster than the US market
High Growth Earnings: Insufficient data to determine if BMRA's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if BMRA's revenue is forecast to grow faster than the US market.
High Growth Revenue: Insufficient data to determine if BMRA's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if BMRA's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/01/10 07:55 |
End of Day Share Price | 2025/01/10 00:00 |
Earnings | 2024/08/31 |
Annual Earnings | 2024/05/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Biomerica, Inc. is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Nathan Weinstein | Aegis Capital Corporation |
Andrew D'Silva | B. Riley Securities, Inc. |
Kyle Bauser | Colliers Securities |